Athersys Inc. (ATHX) Upgraded by Zacks Investment Research to "Buy"

Athersys Inc. (ATHX) Upgraded by Zacks Investment Research to "Buy"


Zacks Investment Research currently has $2.25 target price on the biopharmaceutical company's stock. According to Zacks, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life.



from Biotech News